AUTHORS
Vaishali Sanchorawala, MD, Ashutosh D. Wechalekar, MD2, Angela Dispenzieri, MD3, Efstathios Kastritis, MD4, Kenshi Suzuki, MD5, Eugene Scott Swenson, MD, PhD6, Julia Catini, PharmD, MBA7, Chen Yao, PhD8, Hrishikesh P Kulkarni, MSc9, Michaela Liedtke, MD10
AFFILIATIONS
1 Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts, United States
2 National Amyloidosis Center and University College London Hospitals, London, United Kingdom
3 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States
4 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5 Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
6 Clinical Development, Alexion, AstraZeneca Rare Disease, New Haven, Connecticut, United States
7 Global Medical Affairs, Alexion, AstraZeneca Rare Disease, Wilmington, Delaware, United States
8 Clinical Data Science, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, United States
9 Biostatistics, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, United States
10 Stanford Amyloid Center, Stanford University School of Medicine, Palo Alto, California, United States
ABSTRACT
Introduction: Light chain (AL) amyloidosis is a plasma cell dyscrasia (PCD) characterized by the secretion of monoclonal free immunoglobulin light chains (kappa or lambda) that misfold and aggregate into amyloid fibrils that deposit in vital organs and tissues. The current standard of care (SoC), cyclophosphamide, bortezomib, and dexamethasone (CyBorD) plus daratumumab, targets abnormal plasma cells that produce amyloidogenic light chains. Anselamimab (CAEL-101) is an investigational anti-fibril monoclonal antibody (mAb) designed to complement anti-PCD therapy by accelerating the removal of misfolded light chain aggregates and fibrils deposited in organs and tissues. Anselamimab decreased all-cause mortality (ACM) and cardiovascular hospitalizations (CVH) among patients with kappa isotype AL amyloidosis when administered with anti-PCD therapy in the Cardiac Amyloid Reaching for Extended Survival (CARES) trials, CAEL-101-302 (NCT04512235) and CAEL-101-301 (NCT04504825). This analysis evaluated time to ACM and frequency of CVH in patients with kappa isotype AL amyloidosis stratified by daratumumab treatment from both CARES trials.
Methods: Newly diagnosed patients with European modification of Mayo 2004 stage IIIa or IIIb AL amyloidosis were randomized 2:1 to receive anselamimab or placebo with a planned regimen of CyBorD (with or without daratumumab) with a prespecified analysis by light chain isotype (kappa or lambda). The time to ACM and frequency of CVH were evaluated according to daratumumab treatment at baseline and at any time during the study. Time to ACM was estimated using Kaplan-Meier and Cox regression. CVH frequency was analyzed using negative binomial regression. Results were based on unstratified models for ACM and CVH.
Results: Of 406 newly diagnosed patients enrolled in the CARES trials, 72 (17.7%) had kappa isotype AL amyloidosis. Among these patients, 37 (51.4%) received daratumumab at baseline (median age 69 years; 73.0% male) and 53 (73.6%) received daratumumab at any time during the study (median age 69 years; 73.6% male).
Among the patients with kappa isotype, anselamimab was associated with a 53% and 51% reduction in ACM compared with placebo among patients who received daratumumab at baseline (hazard ratio [HR], 0.47; 95% CI, 0.16-1.42; P = 0.172) and those who did not receive daratumumab at baseline (HR, 0.49; 95% CI, 0.19-1.32; P = 0.149), respectively. Similarly, anselamimab was associated with reductions of 52% and 54% in ACM compared with placebo among patients with kappa isotype who either received daratumumab (HR, 0.48; 95% CI, 0.2-1.14; P = 0.09) or did not receive daratumumab (HR, 0.46; 95% CI, 0.12-1.73; P = 0.24), at any time during the study, respectively.
Anselamimab was associated with numerical reductions of 54% and 71% in CVH frequency compared with placebo among patients who received daratumumab at baseline (incidence rate ratio [IRR], 0.46; 95% CI, 0.09-2.45; P = 0.363) and those who did not receive daratumumab at baseline (IRR, 0.29; 95% CI, 0.08-1.09; P = 0.067), respectively. The frequency of CVH was reduced by 39% with anselamimab compared with placebo among patients who received daratumumab at any time during the study (IRR, 0.61; 95% CI, 0.16-2.35; P = 0.474). The frequency of CVH was significantly reduced by 87% with anselamimab compared with placebo among patients who did not receive daratumumab at any time during the study (IRR, 0.13; 95% CI, 0.03-0.59; P = 0.008).
Conclusion: In this exploratory pooled analysis of patients with newly diagnosed Mayo stage IIIa/IIIb kappa isotype AL amyloidosis, anselamimab was associated with lower ACM and fewer CVH compared with placebo regardless of daratumumab exposure. The largest reduction in CVH was observed among patients who did not receive daratumumab during the study. These findings are hypothesis-generating given the small subgroup sample sizes and limited number of events.
DISCLOSURES
Vaishali Sanchorawala, MD: Janssen - Honoraria; Gate Bioscience - Honoraria; Eidos Therapeutics - Honoraria; GlaxoSmithKline - Honoraria; Prothena - Honoraria; AbbVie - Honoraria; Alexion Pharmaceuticals - Honoraria; Janssen - Research Funding; Caelum Biosciences - Research Funding; Takeda - Research Funding; Immix BioPharma - Research Funding; Karyopharm Theraputics - Research Funding; Celgene - Research Funding; Prothena - Research Funding; Gate Bioscience - Research Funding; Oncopeptide - Research Funding; AbbVie - Consultancy (Includes expert testimony); Caelum Biosciences - Consultancy (Includes expert testimony); Gate Bioscience - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Proclara - Consultancy (Includes expert testimony); Protego Biopharma - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony)